Scarlet Therapeutics

Scarlet Therapeutics is a biotechnology company developing a platform for generating therapeutic red blood cells (tRBCs).

Erythroid cell lines are genetically engineered to produce red blood cells carrying high concentrations of therapeutic proteins, exploiting their natural tissue distribution, 120-day circulating lifespan, and immunological shielding properties.

Lead indications are the rare metabolic diseases hyperammonemia and hyperoxaluria, with longer-term targets including oncology and autoimmune disease. The company holds an exclusive licence for the BEL-A erythroid cell line.